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Abstract 
Anaplastic Large Cell Lymphoma (ALCL) is a Non-Hodgkin lymphoma found in children and 
young adults with poor survival rates. ALCLs frequently carry a chromosomal translocation 
that results in expression of the oncoprotein nucleophosmin-anaplastic lymphoma kinase 
(NPM-ALK). The key molecular downstream events required for NPM-ALK triggered 
lymphoma growth are still not entirely clear. Here we show that the AP-1 proteins cJun and 
JunB promote lymphoma development and tumor dissemination in a murine NPM-ALK 
lymphomagenesis model via transcriptional regulation of PDGFRB. Therapeutic inhibition of 
PDGFRB markedly prolonged survival of NPM-ALK transgenic mice and increased the 
efficacy of an ALK-specific inhibitor in transplanted NPM-ALK tumors. Remarkably, inhibition 
of PDGFRs in a late stage patient with refractory NPM-ALK-positive ALCL resulted in 
complete and sustained remission within 10 days of treatment. Our data identify PDGFRB as 
novel cJun/JunB target that could be utilized for a highly effective therapy to cure ALCL. 
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ALCLs are T-cell lymphomas1,2 that comprise 10-20% of all Non-Hodgkin’s lymphoma cases 
in children and 3% in adults3. About half of ALCL cases are positive for NPM-ALK fusion 
proteins caused by t(2;5)(p23;q35) translocation4. ALK translocations or point mutations have 
also been described in DLBCLs (diffuse large B-cell lymphomas) and in several non-
lymphoid neoplasms5-8. Inhibition of ALK fusion proteins by specific compounds such as 
crizotinib showed promising clinical responses in ALCL and NSCLC (non-small cell lung 
cancer)9,10. However, ALK mutations conferring resistance to crizotinib have also been 
reported11.  
Recent studies have linked NPM-ALK expression to induction of AP-1 transcription factors 
JunB and cJun12,13. To investigate their role in NPM-ALK-driven T-cell lymphomas, we 
conditionally deleted cJun and/or JunB in T-cells of transgenic mice carrying the human 
NPM-ALK fusion-tyrosine-kinase under the control of the murine CD4-promotor14 (CD4-NPM-
ALK) (Fig. 1a). Gene deletion was confirmed by DNA genotyping (data not shown), real-time 
PCR, Western blotting and immunohistochemistry (IHC) (Suppl. Fig. S1a-c). Expression of 
oncogenic NPM-ALK in T-cells was not affected by Jun deletion (Suppl. Fig. S1a-c) and all 
genetic cohorts displayed normal T-cell development before lymphoma onset (Suppl. Fig. 
S1d,e; data not shown). As expected, CD4-NPM-ALK mice developed T-cell lymphomas 
around 8 weeks after birth14. The overall survival was not affected by deletion of individual 
Jun proteins (Fig.1b), however, inactivation of both, cJun and JunB, in CD4-NPM-ALK-
CD4ΔΔJun mice resulted in significantly prolonged survival (Fig. 1b). CD4-NPM-ALK-CD4ΔΔJun 
lymphomas showed markedly reduced proliferation and significantly increased apoptosis 
when compared to CD4-NPM-ALK lymphomas (Fig. 1c; Suppl. Fig. S2a,b). Consistently, 
CD4-NPM-ALK-CD4ΔΔJun but not CD4-NPM-ALK lymphoma cells failed to grow in vitro (data 
not shown) and CRE-mediated deletion of cJun/JunB in established CD4-NPM-ALK-
cJunflox/flox;JunBflox/flox cell lines induced cell death (Suppl. Fig. S2c). However, freshly isolated 
CD4-NPM-ALK-CD4ΔΔJun lymphoma cells formed palpable tumors when engrafted into SCID 
mice, albeit after a long latency (Suppl. Fig. S2d). These data demonstrate that cJun and 
JunB are critical regulators of NPM-ALK driven T-cell lymphoma development. 
T-cell lymphomas spread to many organs in CD4-NPM-ALK transgenic mice14. Although 
CD4-NPM-ALK-CD4ΔΔJun mice eventually developed lymphomas, we failed to detect 
dissemination of tumor cells (Fig. 1d,e; Suppl. Fig. S2e). Importantly, blood vessel numbers 
were significantly decreased in primary lymphomas of CD4-NPM-ALK-CD4ΔΔJun when 
compared to CD4-NPM-ALK controls (Fig. 2a). Surprisingly, expression and activation of the 
mural pericyte cell marker PDGFRB (platelet derived growth factor receptor beta) was readily 
detectable in lymphoma cells of CD4-NPM-ALK mice but essentially absent in T-cell 
lymphomas of CD4-NPM-ALK-CD4ΔΔJun mice (Fig. 2b,c). Tumor cells from single CD4-NPM-
ALK-CD4ΔJunB and CD4-NPM-ALK-CD4ΔcJun mice displayed intermediate PDGFRB protein 
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expression (Suppl. Fig. S3a). PDGFRB mRNA expression was also decreased in 
lymphomas of CD4-NPM-ALK-CD4ΔΔJun mice when compared to CD4-NPM-ALK lymphomas 
(Fig. 2d) suggesting a transcriptional regulation of PDGFRB by Jun proteins. Consistently, 
AP-1 consensus sequences were identified within the murine PDGFRB promoter and first 
intron that were conserved among other species (Suppl. Fig. S3b,c)15,16. Moreover, analysis 
of ENCODE transcription factor binding tracks revealed binding of cJun and JunB to the 
PDGFRB intronic AP-1 site in the human K562 leukemia cell line (Suppl. Fig. S3d)15,17. 
EMSA analysis of nuclear extracts from NPM-ALK lymphomas demonstrated AP-1 DNA 
binding to the consensus sequence, which was reduced after antibody-mediated cJun and 
JunB depletion (Fig. 2e). Moreover, cJun/JunB binding to the PDGFRB promoter was 
confirmed by Chromatin Immunoprecipitation (ChIP) assays of human dermal fibroblasts 
(Fig. 2f), murine NPM-ALK cell lines and tumor tissues (Suppl. Fig S3e,f) as well as 
luciferase reporter assays in Jurkat cells (Fig. 2g) or in HeLa cells using PDGFRB promoter 
constructs with and without an AP-1 site (Suppl. Fig. S3g). These data demonstrate 
transcriptional regulation of PDGFRB by cJun and JunB. 
PDGFRs have not been implicated in ALCL but are known physiologic regulators of tumor 
growth18-20. We therefore investigated the effects of the PDGFR kinase inhibitor imatinib on 
established murine lymphoma cell lines. Imatinib also blocks BCR-ABL, KIT and PDGFRA 
activity with high affinity21, but has no effect on ALK22,23. The NPM-ALK lymphoma cell lines 
lacked BCR-ABL (data not shown) and PDGFRA expression whereas KIT was expressed at 
variable levels (Fig. 3a, Suppl. Fig. S4a,b).  PDGFRB expression ranged from high to non-
detectable levels (Figure 3a; Suppl. Fig. S4a). The effects of imatinib on tumor growth were 
then evaluated in tumor cell transplantation experiments. Importantly, imatinib treatment of 
tumor bearing mice resulted in markedly reduced tumor growth (Fig. 3b; Suppl. Fig. S4c). 
The response rate of individual transplanted cell lines correlated with the level of PDGFRB 
expression since A333-derived lymphomas (lack PDGFRB but express high levels of c-Kit) 
were not affected by imatinib treatment (Fig. 3b). Similar results were obtained using nilotinib 
(Suppl. Fig. S4d), another PDGFRB kinase inhibitor24,25. Neither expression of cytokines and 
their receptors implicated in ALCL lymphomagenesis such as IL-9 and IL-2226,27 (Suppl. Fig. 
S4e), nor peripheral and splenic T-cell populations (Suppl. Fig. S5a-c) or tumor infiltrating T 
subsets (Suppl. Fig S5d,e) were affected by imatinib treatment. These data demonstrate that 
inhibition of PDGFRB markedly impairs growth of transplanted ALCL tumor cells. 
We next explored the effects of imatinib on primary lymphomas in CD4-NPM-ALK mice. 
Imatinib treatment significantly increased overall survival (Fig. 3c), reduced in vivo tumor cell 
proliferation and enhanced apoptosis (Fig. 3d). Imatinib also blocked proliferation and 
enhanced cell death of murine PDGFRB+ lymphoma cell lines in vitro (Suppl. Fig. S6a,b). As 
expected, imatinib reduced PDGFRB phosphorylation in CD4-NPM-ALK cell lines (Suppl. 
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Fig. S6c) and in tumor tissues of CD4-NPM-ALK mice (Fig. 3e) resulting in blunted AKT and 
STAT3 but not ERK phosphorylation (Suppl. Fig. S6d,e). Moreover, PDGFRB 
phosphorylation of PDGFB-stimulated lymphoma cells was impaired by imatinib in a dose 
dependent manner (Suppl. Fig. S6f,g), resulting in reduced proliferation (Suppl. Fig. S6h). 
Imatinib also reduced PDGFB mRNA levels (Suppl. Fig. S6i) in CD4-NPM-ALK lymphomas, 
indicating an autoregulatory PDGF secretion loop. Remarkably, imatinib-treated CD4-NPM-
ALK-CD4ΔΔJun mice did not develop tumors during the 30 week observation period (Fig. 3c) 
and tumor cell dissemination to distant organs was completely blocked (Suppl. Fig. S7a). 
This is most likely due to an additional effect of imatinib on the tumor stroma as also reported 
for other cancers28,29 (Suppl. Fig. S7b-f).  
We next tested imatinib in combination with the ALK inhibitor crizotinib9. Imatinib and 
crizotinib synergistically reduced tumor growth of grafted NPM-ALK+ lymphomas (Fig. 3f). 
Similar results were obtained with the ALK inhibitor CEP2812230. Moreover, imatinib reduced 
growth and percentage of lymphomas that relapsed after CEP28122 treatment (Fig. 3g,h). 
These data demonstrate that therapeutic blockade of PDGFRs can markedly alleviate 
relapse of ALCLs after ALK inhibition.  
The vast majority of human NPM-ALK+ and NPM-ALK- ALCLs expressed high levels of JunB, 
cJun, PDGFRA and PDGFRB mRNA 31-34 (Fig. 4a) and protein (Fig. 4b; Suppl. Fig. S8a,b). 
Consistently, two highly conserved AP-1 binding sites were identified in the human PDGFRA 
promoter (Suppl. Fig. S8c). KIT and BCR-ABL protein expression as well as KIT mutations 
were not detected (Suppl. Fig. S8d; data not shown). In contrast to lymphomas, established 
human ALK+ ALCL cell lines were negative for PDGFRA/B (Suppl. Fig. S8e) and ALK 
expression was required to maintain JunB mRNA expression (Suppl. Fig. S8f). Our data 
demonstrate that ALK+ human ALCLs express high levels of PDGFRA/B and JunB. 
Based on our results, we obtained ethical approval and informed consent to perform imatinib 
treatment of an ALCL patient with very poor prognosis. The patient suffered from NPM-ALK+, 
JunB+, cJun+, PDGFRA+, PDGFRB+, c-Kit- ALCL (Fig. 4c) that was refractory to conventional 
first line chemotherapy and had relapsed after autologous stem cell transplantation. 
Amazingly, the patient was in complete clinical remission with reduced tumor markers and 
normalized PDGFB levels within 10-14 days of imatinib therapy (Fig. 4d,e,f,g). Of note, we 
also observed high PDGFB levels in the serum of four additional ALCL patients (Suppl. Fig. 
S8g). The patient has now been free of ALCL since 18 months after initiation of imatinib 
therapy. These data demonstrate rapid and complete remission of ALCL in a terminally sick 
patient without other treatment options.  
Here we present evidence that JunB and cJun are crucial for growth and metastasis of ALCL 
lymphomas via regulation of PDGFR expression. PDGFR is not expressed in non-
transformed T-cells and oncogenic NPM-ALK signaling might operate synergistically with 
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cJun/JunB to induce PDGFR. Mechanistically, PDGFR might promote ALCL formation by a 
combined effect on lymphoma cells and tumor stroma. Regulation of PDGFR in the tumor 
stroma and the qualitative contribution of stromal effects to drug responses observed in the 
mouse models used have to be further evaluated. Most importantly, imatinib treatment of a 
terminally ill patient, who was already refractory to conventional therapies, resulted in a 
complete disease remission demonstrating that ALCL can be cured. Our data also identified 
PDGFR inhibition as effective treatment option for tumors that have relapsed after ALK 
inhibition therapy. A clinical trial based on PDGFR expression in tumors is currently designed 
to enroll patients for second line ALCL.  
 
Methods Summary 
Mice carrying the human NPM-ALK fusion-gene were crossed with mice carrying a CD4-Cre 
as well as floxed alleles for JunB and/or cJun. Transplant experiments with CD4-NPM-ALK 
cell lines were performed using SCID mice followed by single or combination treatments with 
imatinib, nilotinib, and/or crizotinib. Balb/c ALK+ ALCL cells were implanted into syngeneic 
Balb/c mice and recipients were treated with CEP28122 or CEP28122 + imatinib. Patient 
formalin fixed paraffin embedded tissues samples were kindly provided by the Clinical 
Institute of Pathology at the Medical University of Vienna after receipt of informed patient 
consent and in accordance with the declaration of Helsinki. Immunostainings were quantified 
with the HistoQuestTM and TissueQuestTM software. Western blot analyses were performed 
using total protein extracts. Chromatin Immunoprecipitation (ChIP) was executed with either 
107 cells or 100 µg of tumor tissue from NPM-ALK lymphomas with and without cJun and/or 
JunB. Luciferase assays were performed using OneGlo and BetaGlo systems (Promega). 
For Electro Mobility Shift Assay (EMSA), cell lysates of NPM-ALK-positive mouse tumors 
were used. Supershift reactions of AP-1 complexes were performed using antibodies specific 
for cJun and JunB. After ethical approval and informed consent, an ALCL patient was treated 
with 400 mg imatinib/day. Platelet-low plasma samples were collected from the ALCL patient 
before and after imatinib treatment and analyzed for CRP, haptoglobin (HP), soluble CD30 
(sTNFRSF8), beta-2-microglobulin (B2M), and PDGFB levels by ELISA. The statistical 
analyses were performed using GraphPad Prism 5 software. The raw data were analyzed 
with either ANOVA and the Tukey Post test or with the Student’s t-test.  
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Figure Legends 
Figure 1. JunB and cJun control survival and spreading of NPM-ALK lymphomas.  
(a) Mouse strains with T-cell-specific CD4-NPM-ALK expression and T-cell-specific deletion 
of either JunB (CD4-NPM-ALK-CD4-JunBΔ/Δ;cJunΔ/+; designated CD4-NPM-ALK-CD4ΔJunB), 
cJun (CD4-NPM-ALK-CD4-cJunΔ/Δ;JunBΔ/+; designated CD4-NPM-ALK-CD4ΔcJun), or both 
(CD4-NPM-ALK-CD4-cJunΔ/Δ;JunBΔ/Δ; designated CD4-NPM-ALK-CD4ΔΔJun) were generated. 
(b) Kaplan-Meier curves depicting overall survival of CD4-NPM-ALK mice carrying deletion of 
JunB, cJun or both. Isogenic wild type mice are shown as control. (c) Sections of CD4-NPM-
ALK and CD4-NPM-ALK-CD4ΔΔJun lymphomas were TUNEL-stained and Ki67-stained to 
assess apoptosis and proliferation, respectively. The mean number of TUNEL- and Ki67-
positive cells among 2000 cells/tumor sample were determined using TissueQuestTM 
software. Data from 5 different mice (mean value +/- SD) are shown. (d) H&E-staining of 
lymphoma and liver tissues of CD4-NPM-ALK and CD4-NPM-ALK-CD4ΔΔJun mice. While 
lymphomas are morphologically similar in both genotypes, there is a massive invasion of 
tumor cells into the liver of CD4-NPM-ALK mice (green arrowheads), which have already 
largely destroyed the liver architecture around the blood vessels (red asterisk). In contrast, 
no disseminated tumor cells were detectable in the liver of CD4-NPM-ALK-CD4ΔΔJun mice 
(red asterisk denotes blood vessel). (e) Periodic acid-Schiff (PAS)-stained livers of CD4-
NPM-ALK and CD4-NPM-ALK-CD4ΔΔJun (small inset) mice. Tumor cells are clearly visible in 
the liver parenchyma (green arrowheads) of CD4-NPM-ALK mice whereas livers of CD4-
NPM-ALK-CD4ΔΔJun mice were free of migrating tumor cells. Red asterisks denote blood 
vessels. 
 
Figure 2. PDGFRB is a direct transcriptional target of JunB and cJun. 
(a) CD31-immunostaining to detect blood vessels in CD4-NPM-ALK and CD4-NPM-ALK-
CD4ΔΔJun lymphomas. Quantitative assessment using HistoQuestTM software of the areas 
indicates a significant increase in vascularization in CD4-NPM-ALK lymphomas (n = 3). Data 
are mean values +/- SD. (b) PDGFRB and phospho-PDGFRB (pPDGFRB) expression in 
CD4-NPM-ALK and CD4-NPM-ALK-CD4ΔΔJun lymphomas. Wild type thymus is shown as a 
negative control. Insets show high magnification (600x). (c) Western blot analysis of 
PDGFRB expression in CD4-NPM-ALK and CD4-NPM-ALK-CD4ΔΔJun lymphomas. 
Expression of β-actin (ACTB) is shown as control. (d) PDGFRB mRNA levels are reduced in 
CD4-NPM-ALK-CD4ΔΔJun tumors when compared to CD4-NPM-ALK tumors (n = 3). PDGFRB 
mRNA levels were analyzed by qPCR. Mean values +/- SD are shown. (e) Electrophoretic 
mobility shift assay (EMSA) analysis using a conserved PDGFRB AP-1 site (PDGFRBAP-1) 
and a mutated version (PDGFRBAP-1 mut). Depletion of JunB and cJun using a mixture of 
monoclonal antibodies (AB) resulted in strong reduction of DNA binding. (f) Chromatin 
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Immunoprecipitation (ChIP) in the human cell line BJ-1 confirmed binding of JunB and cJun 
to the AP-1 consensus sequence in the PDGFRB locus (PDGFRB). Reduced binding was 
observed to a negative 3’ control region (PDGFRBneg) (n = 3). Mean values +/- SEM are 
shown. (g) The functionality of the AP-1 site for PDGFRB promoter regulation was 
demonstrated with a luciferase reporter assay. Jurkat lymphoma cells were transfected with 
the indicated vectors and subjected to OneGlo-luciferase assay after 36hrs. The promoter-
less pGL3 luciferase vector was used as control. Cells were co-transfected with 0.05 µg p-
ßGAL and subjected to a BetaGlo assay for normalization. Mean RLU levels +/- SD are 
shown (n = 3). 
 
Figure 3. PDFGR inhibition interferes with formation of transplanted tumors. (a) 
Western Blot analysis for PDGFRB and PDGFRA expression in different murine cell lines 
isolated from CD4-NPM-ALK lymphomas. HSC-70 (HSPA8) was used as a loading control. 
(b) Tumor weight of transplanted CD4-NPM-ALK cell lines A333 (no PDGFRB expression; n 
= 4), MEL406 (intermediate PDGFRB expression; n = 4), and CD4-417 (high PDGFRB 
expression; n = 8) without (black circles) and with imatinib treatment (blue squares). The 
weight of tumors was determined 7 days after initiation of imatinib treatment. (c) Survival 
curves of untreated and imatinib-treated CD4-NPM-ALK and CD4-NPM-ALK-CD4ΔΔJun mice. 
Treatment was started at 6 weeks of age and mice were sacrificed at 30 weeks of age. (d) 
Proliferation and apoptosis in transplanted CD4-417 lymphoma cells was assessed by Ki67- 
and TUNEL-staining. Representative images are shown. Bar graphs indicate the mean 
positive cell number (+/- SD) as determined by HistoQuestTM software (n = 5). (e) pPDGFRB 
expression levels in untreated (PBS) and imatinib-treated CD4-NPM-ALK mice. (f) Reduction 
of tumor size after treatment of MEL406-transplanted recipient mice with imatinib, crizotinib, 
or both. Mean tumor mass +/- SD is shown. (n = 10 mice per group). (g) Balb/c ALK+ ALCL 
cells (VAC) were implanted into syngeneic Balb/c mice and treated with CEP28122 (100 
mg/kg/bid). Tumors relapsed after 14 days of CEP28122 treatment and were then treated 
with CEP28122 + imatinib (start of treatment is indicated for each mouse by green 
arrowheads). (h) Balb/c mice were injected with syngenic ALK+ ALCL cells. Animals with 
lymphomas larger than 1 cm in diameter were then treated with CEP28122 or CEP28122 + 
imatinib. Data from individual mice are shown.  
 
Figure 4. Complete remission of ALCL in a patient following imatinib treatment. 
(a) Gene expression profiles obtained from three publicly available (GSE6338, GSE14879, 
GSE19069), proprietary, and unpublished datasets including PTCL, ALK- and ALK+ ALCL. 
Note the increased expression of JunB, cJun, genes encoding for Fos AP-1 members and 
PDGFRs. (b) Quantitation of immunohistochemistries for PDGFRA and PDGFRB on > 280 
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human PTCL/NOS, AITL, ALK+ ALCL and ALK- ALCL tumor samples. In contrast to 
PTCL/NOS and AITL, ALCL patient samples displayed high expression of both, PDGFRA 
and B, in most cases. Number of cases with positive staining in italic / total number of cases 
per dataset in standard. The (c) H&E-staining and immunohistochmistry for indicated 
markers on tumor sections from a 27-year old patient with grade III ALK+ ALCL that was 
refractory to standard treatment. (d-g) Imatinib treatment (400 mg/day) led to complete 
remission of ALCL in the patient. (d) Within 10 days of treatment, axillary lymph nodes 
(encircled with white dotted line) became PET-CT-negative. L, lung; H, heart; R, rib-cage. 
(e,f) The serum concentrations of tumor markers beta-2-microglobulin (B2M) and soluble 
CD30 (sTNFRSF8) as well as acute phase parameters haptoglobin (HP) and C-reactive 
protein (CRP) returned to normal levels after imatinib treatment. The transient increase of 
CRP around day 27 (e) was due to an infection of the patient. Normal ranges for B2M and 
HP serum concentrations are indicated by the light green and the light blue areas, 
respectively (f). (g) PDGFB was elevated in platelet-low plasma before treatment in the 
patient and reverted to normal levels (light area) as early as 10 days after initiation of imatinib 
therapy. The patient has remained tumor-free since 18 months. 
 
Methods  
 
Cell culture 
Cell lines CD-4-4, CD-417, MEL406, VAC, bT02, A943 and A333 were isolated from CD4-
NPM-ALK mice and seeded at 1x106 cells/ml in RPMI 1640 Medium supplemented with 10% 
FBS and antibiotics. Cell numbers were determined with an electronic cell counter (CASY-1, 
Schärfe-System).  
 
Mice 
Mice carrying the human CD4-NPM-ALK fusion-gene4,14 were crossed with CD4-Cre mice35, 
as well as floxed JunB and/or cJun mice36,37. The genetic background of these intercrosses 
was C57Bl/6xBalb/c. For the Kaplan-Meier curve, only isogenic littermates of the following 
genotypes were used: wild type control, CD4-NPM-ALK-JunBflox/flox;cJunflox/flox (CD4-NPM-
ALK), CD4-NPM-ALK-CD4-JunBΔ/Δ;cJunΔ/+ (CD4-NPM-ALK-CD4ΔJunB), CD4-NPM-ALK-CD4-
JunBΔ/+;cJunΔ/Δ (CD4-NPM-ALK-CD4ΔcJun) and CD4-NPM-ALK-CD4-JunBΔ/Δ;cJunΔ/Δ (CD4-
NPM-ALK-CD4ΔΔJun) mice. Mice were kept in a specific-pathogen-free facility and all animal 
experiments were done in agreement with the ethical guidelines of the Medical University of 
Vienna.  
 
Xenograft experiments 
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12 week old female SCID mice were subcutaneously implanted with 1-5x106 cells. After two 
weeks, tumors had grown to the size of <1.0 cm and mice received either 100-200 mg/kg/day 
imatinib, nilotinib, crizotinib (100 mg/kg/day), imatinib + crizotinib (33 mg/kg/day) or PBS for 
seven days by oral gavage.  
 
Syngenic engraftment 
1x106 Balb/c ALK+ ALCL cells (VAC and bT02) were subcutaneously implanted into 4-6 week 
old syngeneic Balb/c recipients. Mice with tumor masses of <1.0 cm were treated with 
CEP28122 (100 mg/kg/bid), CEP28122 (100 mg/kg/bid) + imatinib (200 mg/kg/bid) or 
CEP28122 (100 mg/kg/bid) followed by CEP28122 (100 mg/kg/bid) + imatinib (200 
mg/kg/bid).  
 
Imatinib treatment CD4-NPM-ALK tumor bearing mice 
CD4-NPM-ALK-positive mice were treated with imatinib between 6 and 30 weeks of age as 
described for xenograft experiments. All animal experiments were approved by the ethical 
committee for animal experiments of the Medical University of Vienna and the Federal 
Ministry of Science and Research of Austria (animal license numbers: BMWF-66.009/0139-
C/GT/2007, BMWF-66.009/0092-II/10b/2009, BMWF-66.009/0137-II/10b/2010 and BMWF-
66.009/0001-II/3b/2011). 
 
Patient samples, treatment and blood testing 
The ALCL patient was treated under supervision of the Department of Internal Medicine I and 
in agreement with the ethic committee of the Medical University of Vienna with 400 mg 
imatinib/day after receipt of informed consent. Plasma samples were analyzed for CRP and 
haptoglobin concentrations (nephelomteric assays). PDGFB, sCD30 (sTNFRSF8) and beta-
2-microglobulin (B2M) plasma levels were quantified by commercially available ELISAs 
(ebioscience).  
 
Immunohistochemistry and immunofluorescence 
IHC- and IF-stainings were performed with formalin fixed paraffin embedded tissues after 
receipt of informed patient consent and in accordance with the declaration of Helsinki. 
Antibodies used were: anti-Ki67 (Novocastra, NCL-KI67-P), anti-PDGFRA (Neomarkers, RB-
9027), anti-PDGFRB (Cell Signaling, #3169), anti-pPDGFRB (SCBT, sc-12909), anti-
Cleaved Caspase 3 (Cell Signaling, #9661), anti-Stat3 (SCBT, sc-7179), anti-p-Stat3 (Cell 
Signaling, #9145), anti-p-Akt (Cell Signaling, #3787), anti-JunB (SCBT, sc-46), anti-cJun 
(SCBT, sc-1694), anti-cJun (Cell Signaling, #9165), anti-ALK (Zymed, 51-3900), anti-CD30 
(DAKO, M0751), anti-CD31 (Dianova, DIA 310), anti-S100A/B (Dako, Z0311), anti-Collagen 
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IV (Chemicon, AB756P), anti-smooth muscle actin (Neomarkers, MS-113), anti-Vimentin 
(Abcam, AB28028). TUNEL-staining was performed with the “in situ cell death detection kit” 
(Roche) according to the manufacturers instructions. Images were captured with a Zeiss 
AxioImager Z1 microscope and quantified using HistoQuestTM and TissueQuestTM software 
(TissueGnostics GmbH, Vienna, Austria, www.tissuegnostics.com).  
 
ChIP (Chromatin Immunoprecipitation) 
Conserved AP-1 binding sites within the PDGFRB promoter were identified using the ecr 
browser (http://ecrbrowser.dcode.org)38. ChIP was performed as described39. 107 cells (CD4-
417; BJ-1) or 100 µg of tumor tissue (CD4-NPM-ALK or CD4-NPM-ALKΔ/ΔJun lymphomas) 
were used with anti-JunB sc-73X, anti-cJun sc-1694X and control antibodies (normal rabbit 
IgG, Santa Cruz). Primer sequences amplifying a conserved AP-1 binding site in the 
proximal murine PDGFRB promoter were: muPDGFRB-FW: 5'-
CTCCATTTGACAGGCATCAG-3'; muPDGFRB-Rev: 5'-CTTCCTCCTTTCCCTCTGCT-3'. 
For negative control muPDGFRBneg-FW: 5’-TAGGCTGAGCAGGTCAACT-3’; 
muPDGFRBneg-Rev: 5’-TGTGCTCAGGGAGATGACAG-3’ and for positive control 
muVEGF-FW: 5’-AATGGGATCCTCTGGGAAGT-3’ and muVEGF-Rev: 
5’-CACAGTGCATACGTGGGTTT-3’ primers were used. For the human PDGFRB promoter, 
primer sequences were: huPDGFRB-FW: 5'-CAGGTCATCTGCTCCAAGTG-3’ and 
huPDGFRB-Rev: 5'-TTGCACTGTCCTGTCTGTCC-3’ as well as huPDGFRBneg-FW: 
5’-GGGTATATGGCCTTGCTTCA-3’ and huPDGFRBneg-Rev: 
5’-GAGGAATCCCTCACCCTCTC-3’ for negative control.  
 
Promoter analysis and reporter gene assays 
The “UCSC Genome Browser on Mouse, July 2007“15 and “MathInspector”16 were used for in 
silico promoter analysis. Luciferase assays were performed as previously described40. 
PDGFRB-luc and PDGFRBΔ(-w/o AP-1 site)-luc pGL3 vectors (Promega) were cloned by 
PCR. Human cJun and JunB pCDNA3.1 (Invitrogen) expression vectors were used together 
with a beta-gal control vector (pMIR-REPORT; Ambion) for relative luciferase quantification. 
 
Electromobility shift Assay (EMSA)  
Oligonucleotides were annealed at equimolar concentrations (40 µM) in 200 µl annealing 
buffer (0.0625 x PCR buffer II Roche; 0.94 M MgCl2). For supershift reactions, 2 µg of 
antibodies specific for JUNB and JUN (anti-JunB sc-73X, anti-cJun sc-1694X) were used. 
 
Gene expression profiling 
The gene expression data were obtained from three publicly available (GSE6338, 
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GSE14879, GSE19069 at NCBI GEO repository http://www.ncbi.nlm.nih.gov/geo/)31-33, 
proprietary34, and unpublished datasets including T cells from ALCL, PTCL. Expression 
values were extracted from CEL files and normalized with RMA Selected probe lists were 
visualized in a heat map format using Heat Map Viewer available as a GenePattern module. 
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